Interesting data from #STERIMGLI at #EANO2026 on #re-irradiation + #durvalumab for recurrent glioblastoma:

➡️ HF-SRT 24 Gy/3 fx
➡️ Primary OS endpoint not met in ITT population (16.1 vs 13.3 months)
➡️ QoL and cognition maintained
➡️ Exploratory analyses suggest a stronger OS in WHO 2021 glioblastoma